PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550544
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550544
Global injectable drugs market is estimated to be valued at USD 570.11 Billion in 2024 and is expected to reach USD 946.09 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 570.11 Bn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 7.50% | 2031 Value Projection: | US$ 946.09 Bn |
Injectable drugs refer to medications that are administered directly into the body, mostly through veins, muscles or tissues. These are preferred over other drug delivery methods for various critical care therapies, owing to their ability to deliver medications directly into the bloodstream, ensuring rapid onset of action. Advancements in drug delivery technologies have led to development of novel injectable formulations with improved stability, solubility and bioavailability of active pharmaceutical ingredients. Growing prevalence of chronic diseases, rising focus on biologics and targeted drug therapies, and increasing demand for self-administered injectables can drive the market growth.
Global injectable drugs market growth is driven by rising prevalence of chronic diseases such as cancer, diabetes and autoimmune disorders. According to WHO, chronic diseases are estimated to account for over 60% of global deaths. Rapid adoption of biologics and targeted drug therapies for treatment of cancer and autoimmune diseases can also drive the market growth. However, high costs associated with R&D and manufacturing of injectable products can pose challenges for the market players. Risk of needle-stick injuries while administering injectables can also hamper its adoption. Growing demand for self-administered injectables especially for management of chronic diseases can offer growth opportunities in the near future.
This report provides in-depth analysis of the global injectable drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global injectable drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Novartis, Sanofi, GlaxoSmithKline, Gilead Sciences and AbbVie
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global injectable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global injectable drugs market
Detailed Segmentation-